¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ : 2018-08-18

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ : 2018-08-18
±³À°ÀÏÀÚ : 2018-08-18
±³À°Àå¼Ò : The K Hotel º°°ü 2Ãþ ±Ý°­È¦  
±³À°ÁÖÁ¦ : ´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇѽŰæ°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ  
´ã´çÀÚ : ÇѴٹ߼º°æÈ­ÁõÇÐȸ
¿¬¶ôó : 02-720-1594  
À̸ÞÀÏ : ksms1594@hanmail.net      
±³À°Á¾·ù : ½Å°æ°ú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í »çÀüµî·Ï: Àü°øÀÇ 1¸¸¿ø, Àü¹®ÀÇ 3¸¸¿ø, ±âŸ:4¸¸¿ø / ´çÀϵî·Ï: Àü°øÀÇ 2¸¸¿ø, Àü¹®ÀÇ 4¸¸¿ø, ±âŸ: 5¸¸¿ø      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 09:10~09:35 Multiple sclerosis (MS)  º¯¼Ò¿µ(±¹¸³°æÂûº´¿ø) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 09:35~10:10 Neuromyelitis optica (NMO)  ¼®Èï¿­(°è¸íÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 10:20~11:00 Human lymphocyte repertories analysis with next generation sequencing technology  Á¤ÁØÈ£(¼­¿ïÀÇ´ë, Ç×ü°øÇаú) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 11:00~11:20 Overview  ±è¿ìÁØ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 11:20~11:40 Case-based learning I:Anti-MOG disease  ±è¼º¹Î(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 11:40~12:00 Case-based learning II:Systemic autoimmune disease  ±è¼±¿µ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 12:00~12:20 Case-based learning III:Neoplastic and lymphoproliferative diseases  ÀÌÇý¸²(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 13:20~14:00 Poster Presentations  ÇмúÀ§¿øȸ Àüü() 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 14:00~14:50 Platform Presentations  ÀÌ»ó¼ö, ±èÈ£Áø(ÁÂÀå)(ÃæºÏÀÇ´ë, ±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 14:50~15:30 European and American new guidelines for MS treatment: how can the guidelines be adapted to clinical practice in Korea?  ±è¼öÇö(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 15:50~16:10 Kim MJ, Jeun SS, et al.(2017). ¡°Effective combination of methylprednisolone and interferon ¥â-secreting mesenchymal stem cells in a model of multiple sclerosis.¡±. J Neuroimmunol. 2018 Jan 15;314:81-88.  Àü½Å¼ö(°¡Å縯ÀÇ´ë, ½Å°æ¿Ü°ú) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 16:10~16:30 Baek SH, Kim JS, et al.(2018). ¡°Low body mass index can be associated with the risk and poor outcomes of neuromyelitis optica with aquaporin-4 immunoglobulin G in women.¡± J Neurol Neurosurg Psychiatry. 2018 Jan 25.  ¹é¼³Èñ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 16:30~16:50 Hyun JW, Huh SY, et al.(2018). ¡°Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.¡±. Mult Scler. 2018 Mar 7.  ÇöÀç¿ø(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 16:50~17:10 Seok JM, Choi MS , et al.(2017) ¡°Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life.¡± PLoS One. 2017 May 23;12(5).  ¼®Áø¸í(¼º±Õ°üÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ : 2018-08-18""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѺ´¸®ÇÐȸ 8th Ç÷¾×º´¸® ¿¬¼ö±³À° : 2018-08-18
´ÙÀ½±Û ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ 2018³âµµ Á¦2Â÷ ÁöµµÀü¹®ÀÇ ±³À° : 2018-08-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21033 Àü³² ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ È£³²Áöȸ - Á¦298Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-28 0 27 2024-06-18
21032 ¼­¿ï 2024 Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2024-06-28 0 17 2024-06-18
21031 ¼­¿ï (2ÀÏÂ÷)2024³â ´ëÇÑô¼öÇÐȸ 2nd ISCoS Regional Symposium : 2024-06-28 0 18 2024-06-18
21030 ¼­¿ï Á¦31ȸ ´ëÇѱâÃÊÀÇÇÐ Çмú´ëȸ (2ÀÏÂ÷) - ¿Â/¿ÀÇÁ º´Çà : 2024-06-28 0 14 2024-06-18
21029 ´ë±¸ 2024 ´ëÇÑÀÀ±ÞÀÇÇÐȸ Ãá°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-28 0 14 2024-06-18
21028 ¼­¿ï 2024 ´ëÇÑ ¼Ò¾Æ¾Ë·¹¸£±â È£Èí±âÇÐȸ Ãá°èÇмú´ëȸ 1ÀÏÂ÷ : 2024-06-28 0 32 2024-06-18
21027 ºÎ»ê ´ëÇѽÉÀåÇÐȸ ±âÃÊ°úÇבּ¸È¸ ÇÏ°è½ÉÆ÷Áö¾ö 2024 : 2024-06-28 0 9 2024-06-18
21026 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾƳ»ºÐºñÇÐȸ ºñ¸¸¿¬±¸Áý´ãȸ 2024³â 1Â÷ : 2024-06-27 0 9 2024-06-18
21025 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ°øÁߺ¸°ÇÀÇ»çÇùÀÇȸ 3Â÷ ¿Â¶óÀÎ ÇÏ°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-27 0 4 2024-06-18
21024 ºÎ»ê Á¦11Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Ãá°èÁ¾ÇÕ½ÉÆ÷Áö¾ö 1ÀÏÂ÷ : 2024-06-27 0 8 2024-06-18
21023 ´ë±¸ ´ëÇѹæ»ç¼±Á¾¾çÇÐȸ ´ë±¸°æºÏÁöȸ 3Â÷ Áý´ãȸ : 2024-06-27 0 20 2024-06-18
21022 ¼­¿ï ´ëÇѼҾƸ¶ÃëÇÐȸ ¿Â¶óÀÎ 2024³â Èñ±Í³­Ä¡ Áúȯ ¸¶Ãë ÇÁ·ÎÅäÄÝ ¿þºñ³ª : 2024-06-27 0 15 2024-06-18
21021 ¼­¿ï (1ÀÏÂ÷)2024³â ´ëÇÑô¼öÇÐȸ 2nd ISCoS Regional Symposium : 2024-06-27 0 12 2024-06-18
21020 °­¿ø 2024 ö¿ø±ºÀÇ»çȸ 2Â÷ ¿¬¼ö°­ÁÂ_ÃÖ±Ù ÀÇÇÐÁö°ß(Ä¡¸Å, ¹é³»Àå°ú ³ë¾È) 0 8 2024-06-18
21019 ¼­¿ï Á¦31ȸ ´ëÇѱâÃÊÀÇÇÐ Çмú´ëȸ (1ÀÏÂ÷) - ¿Â/¿ÀÇÁ º´Çà : 2024-06-27 0 7 2024-06-18
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷